Development of a multidimensional machine learning framework for predicting post-stroke cognitive impairment: A prospective cohort study. [PDF]
Clin Transl MedClinical and Translational Medicine, Volume 15, Issue 12, December 2025.
He A +9 more
europepmc +2 more sources
An Updated Economic Evaluation of HLA-B*58:01 Genotype Testing in Gouty Patients for Preventing Severe Allopurinol Hypersensitivity in Thailand. [PDF]
ACR Open RheumatolObjective Human Leukocyte Antigen (HLA), specifically HLA‐B*58:01, testing before allopurinol initiation in patients with gout in Thailand was previously shown to be cost‐effective. However, several drugs are available in the treatment of gout in Thailand, so the updated cost‐effectiveness analysis is warranted.
Dilokthornsakul P +14 more
europepmc +2 more sources
2024 Update of Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout Part I: Recommendations for General Patients. [PDF]
Int J Rheum DisABSTRACT Background In 2018, the Chinese Society of Endocrinology developed the “Chinese guideline for diagnosis and treatment of hyperuricemia and gout (2019)”. Over the past 5 years, clinical and experimental research has expanded our knowledge of gout, resulting in novel diagnostic and therapeutic approaches.
Sun M +30 more
europepmc +2 more sources
Hyperuricemia – A narrative review
Tungs’ Medical Journal, 2022 Gout is an inflammatory disease caused by the accumulation of monosodium urate crystals in joints, cartilage, synovial bursa, tendons, and soft tissues. Gout is highly associated with hyperuricemia.
Chieh Chen
doaj +1 more source
Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update
Medicina, 2021 This article aims to critically review the evidence on the available therapeutic strategies for the treatment of hyperuricemia. For this reason, several papers were reviewed.
Arrigo F. G. Cicero +3 more
doaj +1 more source
Review of Urate-Lowering Therapeutics: From the Past to the Future
Frontiers in Pharmacology, 2022 We reviewed all currently available ULT, as well as any medications in development using following databases: United States Food and Drug Administration (FDA), European Medicines Agency (EMA), Japanese Pharmaceutical and Medical Devices Agency (PMDA ...
Christopher Jenkins +7 more
doaj +1 more source
Научно-практическая ревматология, 2022 The article provides an overview of new and promising drugs aimed at anti-inflammatory and urate-lowering therapy of gout, both already registered and used in clinical practice, and at the stages of implementation or clinical research and demonstrating ...
A. A. Garanin +2 more
doaj +1 more source
Urate-Lowering Therapy May Prevent the Development of Coronary Artery Disease in Patients With Gout
Frontiers in Medicine, 2020 Substantial evidence has demonstrated a close relationship between hyperuricemia and cardiovascular (CV) diseases, but few studies have explored the possibility of using urate-lowering therapy (ULT) to attenuate the development of CV diseases. To compare
Fu-Shun Yen +11 more
doaj +1 more source
Biomedicines, 2023 Chronic kidney disease (CKD) is a major global health problem for which there are no curative drug treatments. Hyperuricemia is one of risk factors for CKD.
Hidekatsu Yanai +3 more
doaj +1 more source
Nephrolithiasis against type 2 diabetes mellitus: on the effect of hypoglycemic therapy on lithogenesis [PDF]
Терапевтический архив, 2018 Aim. To study the effects of oral hypoglycemic agents that can affect the probability of recurrence of nephrolithiasis. Materials and methods. The article is based on the results of examination and treatment of 315 patients suffering from recurrent ...
S K Yarovoy, E N Kareva, O V Djalilov
doaj +1 more source